Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily, next-generation CFTR (cystic fibrosis transmembrane conductance regulator) modulator. ALYFTREK is approved for the treatment of cystic fibrosis (CF) in…
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has granted approval for BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) as a treatment for patients with metastatic…
JCR Pharmaceuticals Co., Ltd. (TSE 4552) today announced the dosing of the first patient in its Phase III clinical trial of JR-142 (INN: redalsomatropin alfa) in Japan. This marks a significant milestone for the company in the development of JR-142,…
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a leading biotech and agtech R&D company focused on developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, has announced positive preliminary results from a recent study. Conducted in collaboration with the University…
Quantum-Si Incorporated (Nasdaq: QSI), known as The Protein Sequencing Company™, has announced the submission of a new preprint paper to BioRxiv, showcasing the power of its proprietary bioinformatics tool, ProteoVue, in detecting and quantifying Single Amino Acid Variants (SAAVs). The…
Bruker has announced the installation of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, a collaborative research center jointly operated by the University of Basel, ETH Zürich, and the University of Zürich. This…
MIRAILAB BIOSCIENCE Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Megumi Tanaka) has partnered with Global Ocean Distribution Pte Ltd (Headquarters: Circular Road; Director: Getty Poon) to introduce its premium supplement brand MIRAI LAB, which features β-Nicotinamide Mononucleotide (β-NMN), to the Singapore market.…
Peter Hinchliffe, CEO of MedLumics, stated, “This marks a key milestone in validating a definitive Atrial Fibrillation (AF) ablation system, utilizing Pulsed Field Ablation (PFA) and Optical Coherence Reflectometry (OCR) to monitor and confirm ablation success in real-time under direct…
A recent survey commissioned by Weave (NYSE: WEAV) sheds light on how patients across different generations are increasingly turning to the internet for health-related information and how this influences their interactions with healthcare providers. The study, conducted among 1,000 U.S.-based…
Sorriso Pharmaceuticals, a biopharmaceutical company focused on developing novel oral antibodies for immune-mediated diseases, today announced positive results from its Phase 1b clinical trial of SOR102. This oral, dual-acting biologic targets TNFα and IL-23 and was tested in patients with…
